Evidence map›Paper›PMID 38958972›Full record

ArticleInvestigative ophthalmology & visual science2024

Epithelial Membrane Protein 2 (EMP2) Blockade Attenuates Pathological Neovascularization in Murine Oxygen-Induced Retinopathy.

Brian Aguirre, Meng-Chin Lin, Eduardo Araujo, Cheng-Hsiang Lu, David Casero, Michel Sun, Steven Nusinowitz, Justin Hanson, Kara Calkins, Lynn Gordon and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Brian AguirreDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Meng-Chin LinDivision of Neonatology and Developmental Biology, Department of Pediatrics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Eduardo AraujoDepartment of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Cheng-Hsiang LuF. Widjaja Inflammatory Bowel Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States.
David CaseroF. Widjaja Inflammatory Bowel Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States.
Michel SunDepartment of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Steven NusinowitzDepartment of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Justin HansonDepartment of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Kara CalkinsDivision of Neonatology and Developmental Biology, Department of Pediatrics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Lynn GordonDepartment of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Madhuri WadehraDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.
Alison ChuDivision of Neonatology and Developmental Biology, Department of Pediatrics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Vision Research Core at UCLAP30EY000331 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVID S WILLIAMS · 1985 to 2026
$16.8M
Targeting epithelial membrane protein 2 (EMP2) in retinopathy of prematurityR01EY032561 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHU, ALISON · 2021 to 2025
$2.0M
Using EMP2 for Image Guided Drug Delivery for Breast CancerR01CA163971 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OLAFSEN, TOVE, WADEHRA, MADHURI · 2012 to 2016
$1.6M
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA163971NEI NIH HHS P30 EY000331NEI NIH HHS R01 EY032561
6 · The paper itself

Abstract

Purpose: Retinopathy of prematurity (ROP) results from postnatal hyperoxia exposure in premature infants and is characterized by aberrant neovascularization of retinal blood vessels. Epithelial membrane protein-2 (EMP2) regulates hypoxia-inducible factor (HIF)-induced vascular endothelial growth factor (VEGF) production in the ARPE-19 cell line and genetic knock-out of Emp2 in a murine oxygen-induced retinopathy (OIR) model attenuates neovascularization. We hypothesize that EMP2 blockade via intravitreal injection protects against neovascularization. Methods: Ex vivo choroid sprouting assay was performed, comparing media and human IgG controls versus anti-EMP2 antibody (Ab) treatment. In vivo, eyes from wild-type (WT) mice exposed to hyperoxia from postnatal (P) days 7 to 12 were treated with P12 intravitreal injections of control IgG or anti-EMP2 Abs. Neovascularization was assessed at P17 by flat mount imaging. Local and systemic effects of anti-EMP2 Ab treatment were assessed. Results: Choroid sprouts treated with 30 µg/mL of anti-EMP2 Ab demonstrated a 48% reduction in vessel growth compared to control IgG-treated sprouts. Compared to IgG-treated controls, WT OIR mice treated with 4 µg/g of intravitreal anti-EMP2 Ab demonstrated a 42% reduction in neovascularization. They demonstrated down-regulation of retinal gene expression in pathways related to vasculature development and up-regulation in genes related to fatty acid oxidation and tricarboxylic acid cycle respiratory electron transport, compared to controls. Anti-EMP2 Ab-treated OIR mice did not exhibit gross retinal histologic abnormalities, vision transduction abnormalities, or weight loss. Conclusions: Our results suggest that EMP2 blockade could be a local and specific treatment modality for retinal neovascularization in oxygen-induced retinopathies, without systemic adverse effects.

Indexed as

OxygenRetinal NeovascularizationRetinopathy of PrematurityAnimalsAnimals, NewbornDisease Models, AnimalHumansHyperoxiaIntravitreal InjectionsMembrane GlycoproteinsMiceMice, Inbred C57BLVascular Endothelial Growth Factor AEmp2 protein, mouseMembrane GlycoproteinsOxygenVascular Endothelial Growth Factor A

Identifiers

PMID38958972
PMCPMC11223617

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.